- Home
- ADSE vs ANAB Comparison
ADSE vs ANAB Comparison
Compare ADSE & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADSE
- ANAB
- Stock Information
- Founded
- ADSE 1980
- ANAB 2005
- Country
- ADSE Ireland
- ANAB United States
- Employees
- ADSE N/A
- ANAB N/A
- Industry
- ADSE Industrial Specialties
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- ADSE Consumer Discretionary
- ANAB Health Care
- Exchange
- ADSE Nasdaq
- ANAB Nasdaq
- Market Cap
- ADSE 647.1M
- ANAB 621.1M
- IPO Year
- ADSE N/A
- ANAB 2017
- Fundamental
- Price
- ADSE $12.98
- ANAB $20.33
- Analyst Decision
- ADSE
- ANAB Buy
- Analyst Count
- ADSE 0
- ANAB 10
- Target Price
- ADSE N/A
- ANAB $48.00
- AVG Volume (30 Days)
- ADSE 52.6K
- ANAB 444.8K
- Earning Date
- ADSE 09-12-2025
- ANAB 08-06-2025
- Dividend Yield
- ADSE N/A
- ANAB N/A
- EPS Growth
- ADSE N/A
- ANAB N/A
- EPS
- ADSE N/A
- ANAB N/A
- Revenue
- ADSE $113,896,884.00
- ANAB $123,164,000.00
- Revenue This Year
- ADSE $219.58
- ANAB $11.22
- Revenue Next Year
- ADSE N/A
- ANAB $8.35
- P/E Ratio
- ADSE N/A
- ANAB N/A
- Revenue Growth
- ADSE 2.45
- ANAB 304.17
- 52 Week Low
- ADSE $9.00
- ANAB $12.21
- 52 Week High
- ADSE $16.35
- ANAB $40.70
- Technical
- Relative Strength Index (RSI)
- ADSE 65.03
- ANAB 38.61
- Support Level
- ADSE $11.76
- ANAB $19.68
- Resistance Level
- ADSE $12.45
- ANAB $20.81
- Average True Range (ATR)
- ADSE 0.73
- ANAB 0.82
- MACD
- ADSE 0.14
- ANAB 0.10
- Stochastic Oscillator
- ADSE 89.07
- ANAB 33.33
About ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. ADSE generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).